Acceptable Toxicity And Good Hematological And Renal Responses After Autologous Hematopoietic Stem Cell Transplantation In Multiple Myeloma Patients With Renal Insufficiency At Transplant: A Prospective Sfgm-Tc Observational Study
BLOOD(2020)
摘要
Background: High dose melphalan (HDM) followed by autologous hematopoietic stem cell transplantation (ASCT) is widely used in multiple myeloma (MM) patients as upfront and salvage therapy. However, the safety and efficacy of ASCT in patients with renal insufficiency (RI) is controversial, which have led to an inconsistent arbitrary cut-off for creatinine clearance (CrCl) for performing ASCT. Here we analyzed prospectively the outcomes of MM patients with severe RI who underwent ASCT.
更多查看译文
关键词
multiple myeloma patients,multiple myeloma,good hematological,renal insufficiency
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要